Literature DB >> 7594497

TGF-beta enhances macrophage ability to produce IL-10 in normal and tumor-bearing mice.

H Maeda1, H Kuwahara, Y Ichimura, M Ohtsuki, S Kurakata, A Shiraishi.   

Abstract

In the present study, we demonstrate that TGF-beta is capable of enhancing macrophage ability to produce IL-10 in normal and EL4 tumor-bearing mice. We found the increase in IL-10 in ascitic fluid and IL-10 mRNA expression in macrophages in parallel with the TGF-beta level and tumor progression. The macrophage production of IL-10 in the tumor-bearing mice was significantly enhanced without LPS stimulation in vitro, compared with normal controls. To clarify the mechanism wherein increased IL-10 production was induced, anti-TGF-beta or anti-IL-10 Abs were administered to EL4-bearing mice. Administration of anti-TGF-beta Ab led to a reduction in the IL-10 contents in ascitic fluid of tumor-bearing mice; however, anti-IL-10 Ab administration did not prevent the increase in TGF-beta contents. Enhanced IL-10 production and mRNA expression of macrophages from the tumor-bearing mice were also reduced by anti-TGF-beta Ab administration. Both anti-TGF-beta and anti-IL-10 Ab administration restored the TNF-alpha production by macrophages in EL4-bearing mice. In normal macrophages, in vitro pretreatment with TGF-beta 1 potentiated IL-10 production, and when natural TGF-beta 1 was administered to normal mice, the recovered peritoneal macrophages showed enhanced IL-10 production. Based on the above findings it can be concluded that TGF-beta enhances macrophage ability to produce IL-10, which sheds a new light on the role of TGF-beta in the immune system.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7594497

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

1.  Interleukin 10 treatment for rheumatoid arthritis.

Authors:  E W St Clair
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  IL-10 enhances IL-2-induced proliferation and cytotoxicity by human intestinal lymphocytes.

Authors:  E C Ebert
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

Review 3.  Control of immune pathology by IL-10-secreting regulatory T cells.

Authors:  S Fowler; F Powrie
Journal:  Springer Semin Immunopathol       Date:  1999

4.  Circulating immunoglobulin-bound transforming growth factor beta at a late tumour-bearing stage impairs antigen-specific responses of CD4+ T cells.

Authors:  M Harada; K Tatsugami; M Nomoto; K Nomoto
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

5.  Polarization of allogeneic T-cell responses by influenza virus-infected dendritic cells.

Authors:  Sangkon Oh; Maryna C Eichelberger
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  IL-15 converts human intestinal intraepithelial lymphocytes to CD94 producers of IFN-gamma and IL-10, the latter promoting Fas ligand-mediated cytotoxicity.

Authors:  Ellen C Ebert
Journal:  Immunology       Date:  2005-05       Impact factor: 7.397

Review 7.  TGF-β signaling and its targeting for glioma treatment.

Authors:  Jianfeng Han; Christopher A Alvarez-Breckenridge; Qi-En Wang; Jianhua Yu
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

8.  TGF-β limits IL-33 production and promotes the resolution of colitis through regulation of macrophage function.

Authors:  Reena Rani; Alan G Smulian; David R Greaves; Simon P Hogan; De'Broski R Herbert
Journal:  Eur J Immunol       Date:  2011-05-27       Impact factor: 5.532

9.  Cytokine expression in squamous intraepithelial lesions of the uterine cervix: implications for the generation of local immunosuppression.

Authors:  S L Giannini; W Al-Saleh; H Piron; N Jacobs; J Doyen; J Boniver; P Delvenne
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

10.  Intravenous tolerance modulates macrophage classical activation and antigen presentation in experimental autoimmune encephalomyelitis.

Authors:  Hongmei Li; Bogoljub Ciric; Jingxian Yang; Hui Xu; Denise C Fitzgerald; Mohamed Elbehi; Zoe Fonseca-Kelly; Shuo Yu; Guang-Xian Zhang; Abdolmohamad Rostami
Journal:  J Neuroimmunol       Date:  2009-02-01       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.